Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal

3 May 2016 12:00

RNS Number : 0664X
Feedback PLC
03 May 2016
 

3 May 2016

 

Feedback plc

("Feedback" or the "Company")

 

Disposal

 

Feedback plc (AIM: FDBK), the medical imaging software company is pleased to announce that it has agreed to sell its 50% equity interest in Stone Checker Software Ltd ('Stone Checker') to Free Association Books Limited, a company connected to one of Feedback's directors, Trevor Brown, for a cash consideration of £46,000 (the "Disposal").

 

Feedback invested £1,000 in Stone Checker in July 2015 and subsequently licensed its TexRAD software to Stone Checker for exclusive use in urolithiasis (kidney stones). On 28 September 2015, Feedback announced the intention to develop a product incorporating TexRAD for kidney stones. It was further stated that the vision of Stone Checker was to develop a composite risk stratification software product incorporating TexRAD CT texture analysis with other known clinical markers. This integrated product could potentially assist urologists and radiologists to provide better patient management and treatment decisions for improved patient outcomes.

 

Stone Checker is making good progress and is reaching the stage where it will require substantial additional investment. Feedback has already announced that it is committing significant resources in developing a lung cancer stratification tool in conjunction with Alliance Medical Group. Accordingly, although urolithiasis could be an exciting application for TexRAD, the directors of Feedback are of the opinion that they should focus investment in TexRAD's use in oncology. The sale of the equity interest in Stone Checker will generate a profit of £45,000 before expenses. Feedback will continue to receive royalty and licence payments should Stone Checker achieve commercial success. The sale proceeds will be used by Feedback for general corporate purposes.

 

Stone Checker is currently a pre-revenue company which made a loss before tax for the period ending 29 February 2016 of £154.

 

Related Party Transaction

 

Trevor Brown is a director and substantial shareholder in Feedback. Dr Balaji Ganeshan is a director of Stone Checker representing Feedback and is expected to remain a director of both Feedback and Stone Checker after the Disposal. Accordingly, the Disposal constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies ("AIM Rules"). The other three directors of Feedback have no direct involvement in Stone Checker and are not related to the purchaser of Feedback's holding and are therefore deemed to be independent under the AIM Rules for the purposes of considering the related party transaction (the "Independent Directors"). The Independent Directors, having consulted with Allenby Capital Limited, the Company's nominated adviser, consider that the terms of the disposal are fair and reasonable insofar as the Company's shareholders are concerned.

 

For further information, contact:

Feedback plc

Tom Charlton / Mike Hayball

Tel: 01954 718072

 

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Simon Clements / James Thomas

Tel: 020 3328 5656

 

Peterhouse Corporate Finance Ltd (Joint Broker)

Lucy Williams / Duncan Vasey 

Tel: 020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISAJMMTMBAMBFF
Date   Source Headline
25th Mar 20247:00 amRNSNew tuberculosis partnership in India
21st Mar 20247:00 amRNSFurther CDC Pilot Programme Secured
23rd Feb 202411:03 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSHalf-year Report
21st Feb 20247:00 amRNSMedical Imaging Partnership Pilot Agreement
6th Feb 20247:00 amRNSNotice of Results & Investor Presentation
19th Dec 20237:01 amRNSHalf Year Trading Update
19th Dec 20237:00 amRNSAward of Pilot Funding
26th Oct 20232:24 pmRNSResult of AGM
25th Oct 20235:53 pmRNSDirector Dealing
27th Sep 202312:15 pmRNSNotice of AGM
12th Sep 20237:00 amRNSFinal Results
5th Sep 20237:00 amRNSNotice of Results & Investor Presentation
19th Jun 20237:00 amRNSYear End Trading Update
4th Apr 20237:00 amRNSBleepa-CareLocker contract extension with QVH
7th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:56 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSNotice of Results, Analyst & Investor Presentation
22nd Dec 202212:08 pmRNSDirector/PDMR Shareholding: Correction
22nd Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20227:00 amRNSHalf Year Trading Update
1st Nov 20223:36 pmRNSTotal Voting Rights
13th Oct 20222:55 pmRNSResult of AGM & Proposed Share Consolidation
29th Sep 20223:46 pmRNSHolding(s) in Company
20th Sep 20223:26 pmRNSNotice of AGM & Proposed Share Consolidation
20th Sep 20227:00 amRNSFinal Results
13th Sep 20227:00 amRNSNotice of Results & Investor Presentation
6th Sep 20227:00 amRNS12 month contract for Sussex CDC pilot extension
19th Jul 20227:00 amRNSContract Update
16th Jun 20227:00 amRNSYear End Trading Update
1st Jun 20227:00 amRNSTrading Update & Director Appointment
12th May 202212:44 pmRNSChange of Registered Office
12th Apr 20227:00 amRNSBleepa wins two NHS Contract Awards
31st Mar 20227:00 amRNSBleepa TB Screening Pilot Now Live in Odisha
23rd Feb 20227:00 amRNSGrant of Options and PDMR dealing
10th Feb 20227:00 amRNSInterim Results
31st Jan 20227:00 amRNSNotice of Results
13th Dec 20217:00 amRNSPartnership with Amazon Web Services
6th Dec 20213:06 pmRNSHolding(s) in Company
2nd Dec 202110:20 amRNSDirector/PDMR Shareholding
2nd Dec 20219:54 amRNSHolding(s) in Company
1st Dec 20214:27 pmRNSHolding(s) in Company
1st Dec 20213:09 pmRNSHolding(s) in Company
30th Nov 20214:05 pmRNSHolding(s) in Company
29th Nov 20211:36 pmRNSDirector Appointment
29th Nov 20211:35 pmRNSResults of AGM, Open Offer, Issue of Equity & TVR
18th Nov 202112:15 pmRNSHolding(s) in Company
16th Nov 20214:35 pmRNSPrice Monitoring Extension
2nd Nov 20211:52 pmRNSResult of Placing
2nd Nov 20217:01 amRNSProposed Placing and Open Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.